Insider Transactions in Q1 2021 at Bridge Bio Pharma, Inc. (BBIO)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2021
|
Charles J Homcy |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.04%
|
$37,204
$71.91 P/Share
|
|
Mar 01
2021
|
Charles J Homcy |
BUY
Grant, award, or other acquisition
|
Direct |
1,521
+0.13%
|
-
|
|
Feb 17
2021
|
Randal W. Scott |
BUY
Open market or private purchase
|
Direct |
16,000
+43.24%
|
$992,000
$62.5 P/Share
|
|
Feb 17
2021
|
Neil Kumar Chief Executive Officer |
BUY
Payment of exercise price or tax liability
|
Direct |
16,000
+0.34%
|
$992,000
$62.5 P/Share
|
|
Feb 17
2021
|
Brian C Stephenson Secretary, Treasurer & CFO |
BUY
Open market or private purchase
|
Direct |
8,000
+2.6%
|
$496,000
$62.5 P/Share
|
|
Feb 17
2021
|
Kkr Genetic Disorder L.P. |
SELL
Open market or private sale
|
Indirect |
3,450,000
-10.0%
|
$207,000,000
$60.47 P/Share
|
|
Feb 16
2021
|
Neil Kumar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,139
-0.05%
|
$136,896
$64.98 P/Share
|
|
Feb 16
2021
|
Neil Kumar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,129
+0.11%
|
-
|
|
Feb 16
2021
|
Brian C Stephenson Secretary, Treasurer & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
592
-0.2%
|
$37,888
$64.98 P/Share
|
|
Feb 16
2021
|
Brian C Stephenson Secretary, Treasurer & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,710
+0.58%
|
-
|